<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="project. fig-count: table-count: ref-count: page-count: Introduction Leishmaniasis is a protozoan" exact="parasitic disease" post="caused by the genus Leishmania. There are more than"/>
 <result pre="leishmaniasis, approximately 20,000â€&quot;30,000 deaths and 0.7â€&quot;1 million new cases of" exact="leishmaniasis" post="occur per annum.1 From the three main forms of"/>
 <result pre="an estimated 50, 000 to 90, 000 new cases of" exact="visceral leishmaniasis" post="(VL) and 600, 000 to 1 million new cases"/>
 <result pre="estimated 50, 000 to 90, 000 new cases of visceral" exact="leishmaniasis" post="(VL) and 600, 000 to 1 million new cases"/>
 <result pre="(VL) and 600, 000 to 1 million new cases of" exact="cutaneous leishmaniasis" post="(CL) occur worldwide annually. Furthermore, more than 90% of"/>
 <result pre="and 600, 000 to 1 million new cases of cutaneous" exact="leishmaniasis" post="(CL) occur worldwide annually. Furthermore, more than 90% of"/>
 <result pre="leishmaniasis (CL) occur worldwide annually. Furthermore, more than 90% of" exact="mucocutaneous leishmaniasis" post="(MCL) cases occur in Bolivia, Brazil, Ethiopia and Peru."/>
 <result pre="(CL) occur worldwide annually. Furthermore, more than 90% of mucocutaneous" exact="leishmaniasis" post="(MCL) cases occur in Bolivia, Brazil, Ethiopia and Peru."/>
 <result pre="no vaccine available for use in humans, the treatment of" exact="leishmaniasis" post="mainly depends on chemotherapy. However, there has been development"/>
 <result pre="toward naturally derived compounds used to treat parasitic diseases including" exact="leishmaniasis" post="for identification of new lead compounds and/or new drugs"/>
 <result pre="with intermediate forms and short flagella were detected. The human" exact="monocytic leukemia" post="cell line THP-1 cells were incubated in RPMI 1640"/>
 <result pre="intermediate forms and short flagella were detected. The human monocytic" exact="leukemia" post="cell line THP-1 cells were incubated in RPMI 1640"/>
 <result pre="of health sciences for providing the laboratory setting. Abbreviations CL," exact="cutaneous leishmaniasis;" post="DMSO, dimethyl sulfoxide; IC50, the half maximal inhibitory concentration;"/>
 <result pre="DMSO, dimethyl sulfoxide; IC50, the half maximal inhibitory concentration; MCL," exact="mucocutaneous leishmaniasis;" post="VL, visceral leishmaniasis. Data Sharing Statement The data used"/>
 <result pre="IC50, the half maximal inhibitory concentration; MCL, mucocutaneous leishmaniasis; VL," exact="visceral leishmaniasis." post="Data Sharing Statement The data used to support the"/>
 <result pre="Salimi ChiraniA. Antileishmanial activity of Urtica dioica extract against zoonotic" exact="cutaneous leishmaniasis." post="PLoS Negl Trop Dis. 2020;14(1):e0007843. doi:10.1371/journal.pntd.000784331929528 16.EssidR, RahaliFZ, MsaadaK,"/>
 <result pre="2010;1(1):66â€&quot;77. 21.Van GriensvenJ, GadisaE, AseffaA, HailuA, BeshahAM, DiroE. Treatment of" exact="cutaneous leishmaniasis" post="caused by Leishmania aethiopica: a systematic review. PLoS Negl"/>
 <result pre="21.Van GriensvenJ, GadisaE, AseffaA, HailuA, BeshahAM, DiroE. Treatment of cutaneous" exact="leishmaniasis" post="caused by Leishmania aethiopica: a systematic review. PLoS Negl"/>
</results>
